Ustekinumab for the treatment of psoriasis

Expert Review of Clinical Immunology

Volumn 7, Issue 2, 2011, Pages 155-164

  Laws, Philip M ^a   Warren, Richard B ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

biological therapy; psoriasis; ustekinumab

Indexed keywords

CUTANEOUS LYMPHOCYTE ASSOCIATED ANTIGEN; ETANERCEPT; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 6; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; USTEKINUMAB;

AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BINDING AFFINITY; BODY WEIGHT; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; FOLLOW UP; HEADACHE; HUMAN; LACTATION; MAXIMUM PLASMA CONCENTRATION; MULTIPLE SCLEROSIS; PREGNANCY; PSORIASIS SEVERITY INDEX; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RHINOPHARYNGITIS; SINGLE DRUG DOSE; TH17 CELL; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION;

ADULT; ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-12; INTERLEUKIN-23; PSORIASIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX;

EID: 79953117927     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.11.4     Document Type: Article

References (65)

1. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 370(9583), 263-271 (2007). (Pubitemid 47069537)
2. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J. Am. Acad. Dermatol. 41(3 Pt 1), 401-407 (1999). (Pubitemid 29418506)
3. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch. Dermatol. Res. 298(7), 321-328 (2006).
4. Najarian DJ, Gottlieb AB. Connections between psoriasis and Crohn's disease. J. Am. Acad. Dermatol. 48(6), 805-821 (2003). (Pubitemid 36706210)
5. Brophy S, Taylor G, Blake D, Calin A. The interrelationship between sex, susceptibility factors, and outcome in ankylosing spondylitis and its associated disorders including inflammatory bowel disease, psoriasis, and iritis. J. Rheumatol. 30(9), 2054-2058 (2003). (Pubitemid 37075561)
6. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 296(14), 1735-1741 (2006). (Pubitemid 44547793)
7. Nestle FO, Kaplan DH, Barker J. Psoriasis. N. Engl. J. Med. 361(5), 496-509 (2009).
8. Leonardi CL, Kimball AB, Papp KA et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 1). Lancet 371(9625), 1665-1674 (2008). Phase III study of ustekinumab for the treatment of chronic plaque psoriasis. (Pubitemid 351671883)
9. Papp KA, Langley RG, Lebwohl M et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371(9625), 1675-1684 (2008). A Phase III study of ustekinumab for the treatment of chronic plaque psoriasis. (Pubitemid 351671884)
10. Smith RL, Eyre S, Warren RB, Young HS, Griffiths CE, Worthington J. No association between polymorphisms in the interleukin-15 gene and early-onset psoriasis in a UK cohort suggests heterogeneity for this susceptibility locus identified in Chinese psoriasis patients. J. Invest. Dermatol. 128(12), 2904-2905 (2008).
11. Reddy M, Torres G, McCormick T et al. Positive treatment effects of ustekinumab in psoriasis: Analysis of lesional and systemic parameters. J. Dermatol. 37(5), 413-425 (2007).
12. Parham C, Chirica M, Timans J et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rb1 and a novel cytokine receptor subunit, IL-23R. J. Immunol. 168(11), 5699-5708 (2002). (Pubitemid 34556153)
13. Warren RB, Brown BC, Carmichael AJ, Griffiths CE. Long-term control of recalcitrant psoriasis with combination infliximab and methotrexate. Clin. Exp. Dermatol. 34(3), 415-416 (2009).
14. Warren RB, Brown BC, Lavery D, Ashcroft DM, Griffiths CE. Biologic therapies for psoriasis: Practical experience in a U.K. tertiary referral centre. Br. J. Dermatol. 160(1), 162-169 (2009).
15. Ryan C, Thrash B, Warren RB, Menter A. The use of ustekinumab in autoimmune disease. Expert Opin. Biol. Ther. 10(4), 587-604 (2010).
16. Gerdes S, Franke J, Domm S, Mrowietz U. Ustekinumab in the treatment of palmoplantar pustulosis. Br. J. Dermatol. 163(5), 1116-1118 (2010).
17. Wohlrab J, Kreft B. Treatment of pityriasis rubra pilaris with ustekinumab. Br. J. Dermatol. 163(3), 655-656 (2010).
18. Kleinpenning MM, Langewouters AM, Van De Kerkhof PC, Greebe RJ. Severe pyoderma gangrenosum unresponsive to etanercept and adalimumab. J. Dermatolog. Treat. DOI:10.3109/09546631003797106 (2010) (Epub ahead of print).
19. Asumalahti K, Ameen M, Suomela S et al. Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. J. Invest. Dermatol. 120(4), 627-632 (2003). (Pubitemid 36344006)
20. Kauffman CL, Aria N, Toichi E et al. A Phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J. Invest. Dermatol. 123(6), 1037-1044 (2004). Phase I study of ustekinumab for the treatment of chronic plaque psoriasis. (Pubitemid 39586823)
21. Gottlieb AB, Cooper KD, McCormick TS et al. A Phase 1, double-blind, placebocontrolled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr. Med. Res. Opin. 23(5), 1081-1092 (2007). Phase I study of ustekinumab for the treatment of chronic plaque psoriasis. (Pubitemid 46799592)
22. Zhu Y, Hu C, Lu M et al. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J. Clin. Pharmacol. 49(2), 162-175 (2009).
23. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 157(4), 238-244 (1978). (Pubitemid 8387357)
24. Feldman SR, Koo JY, Menter A, Bagel J. Decision points for the initiation of systemic treatment for psoriasis. J. Am. Acad. Dermatol. 53(1), 101-107 (2005). (Pubitemid 40826702)
25. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin. Exp. Dermatol. 19(3), 210-216 (1994). (Pubitemid 24194579)
26. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 67(6), 361-370 (1983). (Pubitemid 13098606)
27. Ware JE Jr, Sherbourne CD. The MOS 36-item Short-Form health survey (SF-36). I. Conceptual framework and item selection. Med. Care 30(6), 473-483 (1992).
28. Krueger GG, Langley RG, Leonardi C et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N. Engl. J. Med. 356(6), 580-592 (2007). (Pubitemid 46220818)
29. Griffiths CE, Strober BE, van de Kerkhof P et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N. Engl. J. Med. 362(2), 118-128 (2010). Phase III clinical study directly comparing ustekinumab and etanercept for the treatment of chronic plaque psoriasis.
30. Lebwohl M, Papp K, Han C et al. Ustekinumab improves health-related quality of life in patients with moderate-tosevere psoriasis: Results from the PHOENIX 1 trial. Br. J. Dermatol. 162(1), 137-146 (2010).
31. Langley RG, Feldman SR, Han C et al. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebocontrolled Phase III trial. J. Am. Acad. Dermatol. 63(3), 457-465 (2010).
32. Kim YK, Suh IB, Kim H et al. The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: Effects of psychotropic drugs. Mol. Psychiatry 7(10), 1107-1114 (2002). (Pubitemid 36044270)
33. Gladmann D, Harris ED, Budd RC et al. Psoriatic arthritis. In: Kelley's Textbook of Rheumatology. WB Saunders, PA, USA, 1155-1164 (2004).
34. Gottlieb A, Menter A, Mendelsohn A et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: Randomised, double-blind, placebocontrolled, crossover trial. Lancet 373(9664), 633-640 (2009). Phase II study of ustekinumab for the treatment of psoriatic arthritis.
35. Gladman DD, Helliwell P, Mease PJ, Nash P, Ritchlin C, Taylor W. Assessment of patients with psoriatic arthritis: A review of currently available measures. Arthritis Rheum. 50(1), 24-35 (2004). (Pubitemid 38084284)
36. Kavanaugh A, Menter A, Mendelsohn A, Shen YK, Lee S, Gottlieb AB. Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: A randomized, placebo-controlled, Phase II trial. Curr. Med. Res. Opin. 26(10), 2385-2392 (2010).
37. Lebwohl M, Yeilding N, Szapary P et al. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: Rationale for dosing recommendations. J. Am. Acad. Dermatol. 63(4), 571-579 (2010).
38. Marodi L, Casanova JL. Can primary immunodeficiencies help to provide insights into infectious risks of therapeutic antibodies? Nat. Rev. Immunol. 10(5), 299-300 (2010).
39. Bustamante J, Boisson-Dupuis S, Jouanguy E et al. Novel primary immunodeficiencies revealed by the investigation of paediatric infectious diseases. Curr. Opin. Immunol. 20(1), 39-48 (2008).
40. Zhang SY, Boisson-Dupuis S, Chapgier A et al. Inborn errors of interferon (IFN)-mediated immunity in humans: Insights into the respective roles of IFN-a/b, IFN-g, and IFN-l in host defense. Immunol. Rev. 226, 29-40 (2008).
41. Fortin A, Abel L, Casanova JL, Gros P. Host genetics of mycobacterial diseases in mice and men: Forward genetic studies of BCG-osis and tuberculosis. Ann. Rev. Genomics Hum. Genet. 8, 163-192 (2007).
42. Gordon K, Leonardi C, Lebwohl M et al. The ustekinumab safety experience in patients with moderate-to-severe psoriasis: Results from pooled analyses of Phase 2 and 3 clinical trial data. Poster P 1170. Presented at: EADV Annual Congress. Berlin, Germany, 7-11 October 2009. Pooled analysis of safety data for ustekinumab in the treatment of chronic plaque psoriasis.
43. Warren RB, Brown BC, Lavery D, Griffiths CE. Adalimumab for psoriasis: Practical experience in a U.K. tertiary referral centre. Br. J. Dermatol. 163(4), 859-862 (2010).
44. Smith CH, Anstey AV, Barker JN et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br. J. Dermatol. 161(5), 987-1019 (2009).
45. Lebwohl M, Bagel J, Gelfand JM et al. From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis. J. Am. Acad. Dermatol. 58(1), 94-105 (2008). (Pubitemid 350302037)
46. Doherty SD, Van Voorhees A, Lebwohl MG et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J. Am. Acad. Dermatol. 59(2), 209-217 (2008).
47. Koutruba N, Emer J, Lebwohl M. Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis. Ther. Clin. Risk Manag. 6, 123-141 (2010).
48. Weiss JM, Subleski JJ, Wigginton JM, Wiltrout RH. Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin. Biol. Ther. 7(11), 1705-1721 (2007). (Pubitemid 350157496)
49. Chien AL, Elder JT, Ellis CN. Ustekinumab: A new option in psoriasis therapy. Drugs 69(9), 1141-1152 (2009).
50. Cardenes M, Angel-Moreno A, Fieschi C et al. Oesophageal squamous cell carcinoma in a young adult with IL-12R b 1 deficiency. J. Med. Genet. 47(9), 635-637 (2010).
51. Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: A Phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 7(9), 796-804 (2008).
52. Li J, Gran B, Zhang GX et al. Differential expression and regulation of IL-23 and IL-12 subunits and receptors in adult mouse microglia. J. Neurol. Sci. 215(1-2), 95-103 (2003). (Pubitemid 37272203)
53. Segal BM, Shevach EM. IL-12 unmasks latent autoimmune disease in resistant mice. J. Exp. Med. 184(2), 771-775 (1996). (Pubitemid 26324133)
54. Lee TS, Yen HC, Pan CC, Chau LY. The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 19(3), 734-742 (1999).
55. Hauer AD, Uyttenhove C, de Vos P et al. Blockade of interleukin-12 function by protein vaccination attenuates atherosclerosis. Circulation 112(7), 1054-1062 (2005). (Pubitemid 41174584)
56. Gordon K, Leonardi C, Griffiths CE et al. P-560 - ustekinumab safety update: Cumulative experience from longer term follow-up of patients treated in the ustekinumab psoriasis clinical development program. Presented at: European Academy of Dermatology and Venereology. Gothenberg, Sweden, 6-10 October 2010.
57. Ghislain PD, Poulin Y, Wasel N et al. P589 - maintanence of long-term efficacy of ustekinumab through year 3 for patients with moderate-to-severe psoriasis. Presented at: European Academy of Dermatology and Venereology. Gothenberg, Sweden, 6-10 October 2010.
58. Downs AM. Observational case series on a group of patients with severe psoriasis who failed to respond to antitumour necrosis factor a biologics and switched to ustekinumab. Br. J. Dermatol. 163(2), 433-434 (2010).
59. Clemmensen A, Spon M, Skov L, Zachariae C, Gniadecki R. Responses to ustekinumab in the anti-TNF agent-naive vs. anti-TNF agent-exposed patients with psoriasis vulgaris. J. Eur. Acad. Dermatol. Venereol. DOI: 10.1111/j.1468-3083. 2010.03914.x (2010) (Epub ahead of print).
60. Smith RL, Warren RB, Griffiths CE, Worthington J. Genetic susceptibility to psoriasis: An emerging picture. Genome Med. 1(7), 72 (2009).
61. Warren RB, Smith RL, Campalani E et al. Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. Br. J. Dermatol. 160(2), 438-441 (2009).
62. Ryan C, Menter A, Warren RB. The latest advances in pharmacogenetics and pharmacogenomics in the treatment of psoriasis. Mol. Diagn. Ther. 14(2), 81-93 (2010).
63. Warren RB, Smith RL, Campalani E et al. Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J. Invest. Dermatol. 128(8), 1925-1929 (2008). (Pubitemid 352001201)
64. Zaba LC, Suarez-Farinas M, Fuentes- Duculan J et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J. Allergy Clin. Immunol. 124(5), 1022-1010; e1-e395 (2009).
65. Boy MG, Wang C, Wilkinson BE et al. Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. J. Invest. Dermatol. 129(9), 2299-2302 (2009).